• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FUROSEMIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • FUROSEMIDE chembl:CHEMBL35 Approved

    Alternate Names:

    AQUAMED
    FRUSEMIDE
    FROOP
    LASIX RET
    RUSYDE
    LASIX
    FRUMIL
    TENKOFRUSE
    FRUSID
    LB-502
    NSC-269420
    ALUZINE 40
    DISAL
    ALUZINE 500
    FRUMAX
    FRUSOL
    HYDROLED
    FRUSETIC
    DRYPTAL
    DIURESAL
    FUROSEMIDE
    ALUZINE 20
    FUROSEMID
    DIHYDROFLUMETHIAZIDE
    METHFORYLTHIAZIDINE
    FUROSEMIDU
    2-FURFURYLAMINO-4-CHLORO-5-SULFAMOYLBENZOIC ACID
    4-CHLORO-N-(2-FURYLMETHYL)-5-SULFAMOYLANTHRANILIC ACID
    4-CHLORO-5-SULFAMOYL-N-FURFURYL-ANTHRANILIC ACID
    LASIX (TN)
    FUROSEMIDA
    LASIX®
    FUROSEMIDUM
    4-CHLORO-N-FURFURYL-5-SULFAMOYLANTHRANILIC ACID
    pubchem.compound:3440
    rxcui:4603
    chembl:CHEMBL35
    drugbank:00695
    chemidplus:54-31-9

    Drug Info:

    Year of Approval 1966
    Drug Class antihypertensive agents
    Drug Class diuretics
    Drug Categories sulfanilamides
    FDA Approval 1966
    Drug Indications Diuretics
    Drug Indications Antihypertensive Agents
    Drug Class small molecule
    Drug Categories antihypertensive agents
    Drug Categories antihypertensive agents indicated for hypertension
    Drug Categories drugs causing inadvertant photosensitivity
    Drug Categories drugs that are mainly renally excreted
    Drug Categories high-ceiling diuretics and potassium-sparing agents
    Drug Categories increased diuresis at loop of henle
    Drug Categories nephrotoxic agents
    Drug Categories non potassium sparing diuretics
    Drug Categories oat1/slc22a6 inhibitors
    Drug Categories oat3/slc22a8 inhibitors
    Drug Categories ototoxic agents
    Drug Categories photosensitizing agents
    Drug Categories thyroxine-binding globulin substrates
    Drug Categories ugt1a1 substrates
    (5 More Sources)

    Publications:

    Vormfelde SV et al., 2012, The genetics of loop diuretic effects., Pharmacogenomics J
    Vormfelde et al., 2007, Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs., Clin. Pharmacol. Ther.
    Limmer F et al., 2015, Regulation of the Na(+)-K(+)-2Cl(-) cotransporter by cGMP/cGMP-dependent protein kinase I after furosemide administration., FEBS J
    Davies et al., 1975, Diuretics: mechanism of action and clinical application., Drugs
    Giménez I, 2006, Molecular mechanisms and regulation of furosemide-sensitive Na-K-Cl cotransporters., Curr Opin Nephrol Hypertens
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Brater, 2000, Pharmacology of diuretics., Am. J. Med. Sci.
    Elwood et al., 1991, Loop diuretics inhibit cholinergic and noncholinergic nerves in guinea pig airways., Am. Rev. Respir. Dis.
    Molimard et al., 1995, Furosemide inhibits bradykinin-induced contraction of human bronchi: role of thromboxane A2 receptor antagonism., Eur. J. Pharmacol.
    Ranjbar S et al., 2012, Spectroscopic characterization of furosemide binding to human carbonic anhydrase II., Int J Biol Macromol
    Supuran, 2008, Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides., Curr. Pharm. Des.
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Chandan et al., 1988, Actions of gastrin-releasing peptide and related mammalian and amphibian peptides on ion transport in the porcine proximal jejunum., Regul. Pept.
    de Denus S et al., 2017, A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials., Pharmacogenomics J
    Yang YY et al., 2011, Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites., Clin Sci (Lond)
    Benvenga et al., 1992, Thyroxine binding to the apolipoproteins of high density lipoproteins HDL2 and HDL3., Endocrinology
    Yang et al., 2012, GPR35 is a target of the loop diuretic drugs bumetanide and furosemide., Pharmacology
    Divorty N et al., 2018, The Orphan Receptor GPR35 Contributes to Angiotensin II-Induced Hypertension and Cardiac Dysfunction in Mice., Am J Hypertens
    Divorty N et al., 2015, G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease., Front Pharmacol
  • FUROSEMIDE   SLC12A1

    Interaction Score: 3.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction Sodium-(potassium)-chloride cotransporter 2 inhibitor

    PMIDs:
    17460608 26183401 1092541 16914965 11752352 10653443


    Sources:
    TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • FUROSEMIDE   NPPA-AS1

    Interaction Score: 2.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20877298


    Sources:
    PharmGKB

  • FUROSEMIDE   ADD1

    Interaction Score: 2.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20877298 21692745


    Sources:
    PharmGKB

  • FUROSEMIDE   GPR35

    Interaction Score: 1.19

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Agonist
    Endogenous Drug? False

    PMIDs:
    22236570 29860395 25805994


    Sources:
    DrugBank GuideToPharmacology

  • FUROSEMIDE   GRP

    Interaction Score: 1.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3238049


    Sources:
    NCI

  • FUROSEMIDE   SLC12A2

    Interaction Score: 0.81

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • FUROSEMIDE   APOA1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1446618


    Sources:
    NCI

  • FUROSEMIDE   SLC12A3

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20877298 17460608


    Sources:
    PharmGKB

  • FUROSEMIDE   GNB3

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20877298


    Sources:
    PharmGKB

  • FUROSEMIDE   TAC1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2048822


    Sources:
    NCI

  • FUROSEMIDE   TBXA2R

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7589163


    Sources:
    NCI

  • FUROSEMIDE   ABCC4

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26927285


    Sources:
    PharmGKB

  • FUROSEMIDE   CA2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    22343084 18336309 10592235


    Sources:
    DrugBank

  • FUROSEMIDE   ACE

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20877298


    Sources:
    PharmGKB

  • DrugBank: DB00695

    • Version: 5.1.7

    Alternate Names:
    FUROSEMIDE DrugBank Drug Name
    54-31-9 CAS Number
    Active-Medicated specimen collection kit Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups vet_approved

    Publications:
    Yang et al., 2012, GPR35 is a target of the loop diuretic drugs bumetanide and furosemide., Pharmacology
    Divorty N et al., 2018, The Orphan Receptor GPR35 Contributes to Angiotensin II-Induced Hypertension and Cardiac Dysfunction in Mice., Am J Hypertens
    Divorty N et al., 2015, G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease., Front Pharmacol

  • TEND: FUROSEMIDE

    • Version: 01-August-2011

    Alternate Names:
    FUROSEMIDE Primary Drug Name

    Drug Info:
    Drug Class diuretics
    Drug Class antihypertensive agents
    Year of Approval 1966

    Publications:

  • TdgClinicalTrial: FUROSEMIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Class small molecule
    Drug Indications Antihypertensive Agents
    Drug Indications Diuretics

    Publications:

  • NCI: FUROSEMIDE

    • Version: 14-September-2017

    Alternate Names:
    C515 NCI drug code

    Drug Info:

    Publications:
    Chandan et al., 1988, Actions of gastrin-releasing peptide and related mammalian and amphibian peptides on ion transport in the porcine proximal jejunum., Regul. Pept.
    Benvenga et al., 1992, Thyroxine binding to the apolipoproteins of high density lipoproteins HDL2 and HDL3., Endocrinology
    Elwood et al., 1991, Loop diuretics inhibit cholinergic and noncholinergic nerves in guinea pig airways., Am. Rev. Respir. Dis.

  • PharmGKB: furosemide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Vormfelde SV et al., 2012, The genetics of loop diuretic effects., Pharmacogenomics J
    de Denus S et al., 2017, A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials., Pharmacogenomics J
    Yang YY et al., 2011, Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites., Clin Sci (Lond)

  • GuideToPharmacology: 178101541

    • Version: 29-September-2020

    Alternate Names:
    FUROSEMIDE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • TTD: Furosemide

    • Version: 2020.06.01

    Alternate Names:
    D0PQ3G TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL35

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL35

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2021-04-13